mRNA-5671
Phase 1RNA therapy
ModernamRNA-5671 is one of 66 therapeutic programs targeting Liver Cancer. It is currently in Phase 1.
2
Indications
0
Total Trials
0
Active Trials
65
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Ninlaro
TakedaPreclinical
Prolia
AmgenPreclinical
Eliquis
Bristol-Myers SquibbPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Nolvadex
AstraZenecaPreclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Intron a
Merck & Co.Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Abecma
Bristol-Myers SquibbPreclinical
Oblimersen Sodium
NNational Cancer Institute (NCI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for mRNA-5671. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Modality
- RNA therapy
- Highest Phase
- Phase 1
- Company